HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool?

Abstract
It has been demonstrated that good metabolic control maintained throughout pregnancy can reduce maternal and fetal complications in diabetes. To achieve good metabolic control, before conception and throughout pregnancy, insulin therapy needs to be optimized, and, in this context, the new insulins currently on the market may help. We therefore review here what is known about the potential benefits and risks related to the use of these new insulins in pregnancy. Clinical and experimental data on insulin lispro strongly suggest that lispro does not have adverse maternal or fetal effects during pregnancy in women with preexisting diabetes, and also that its use in these women results in improved glycemic control, fewer hypoglycemic episodes, and improved patient satisfaction. In women with gestational diabetes mellitus (GDM), the use of insulin lispro is efficient in reducing postprandial hyperglycemia and some neonatal features related to hyperglycemia, thus stressing its usefulness in this condition. As for insulin aspart, clinical data on GDM patients shows the same efficacy as insulin lispro in lowering postprandial hyperglycemia, indicating that insulin aspart may be used in GDM when this condition is characterized by postprandial hyperglycemia. The results of a multicentric study now in progress on the efficacy and safety of insulin aspart in type 1 pregnant diabetic patients will definitely be useful in establishing whether this insulin is safe in pregnancy. For the moment, the use of insulin glargine during pregnancy is not recommended owing to the lack of data on maternal and fetal effects.
AuthorsA Lapolla, M G Dalfrà, D Fedele
JournalDiabetes/metabolism research and reviews (Diabetes Metab Res Rev) 2005 May-Jun Vol. 21 Issue 3 Pg. 241-52 ISSN: 1520-7552 [Print] England
PMID15818714 (Publication Type: Journal Article, Review)
CopyrightCopyright 2005 John Wiley & Sons, Ltd.
Chemical References
  • Hypoglycemic Agents
  • Insulin
Topics
  • Diabetes Mellitus, Type 1 (drug therapy, immunology, metabolism)
  • Female
  • Humans
  • Hypoglycemic Agents (administration & dosage, adverse effects)
  • Insulin (administration & dosage, adverse effects, analogs & derivatives)
  • Pregnancy
  • Pregnancy in Diabetics (drug therapy, immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: